+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The endocannabinoid system and Post Traumatic Stress Disorder (PTSD): From preclinical findings to innovative therapeutic approaches in clinical settings

The endocannabinoid system and Post Traumatic Stress Disorder (PTSD): From preclinical findings to innovative therapeutic approaches in clinical settings

Pharmacological Research 111: 668-678

Post-Traumatic Stress Disorder (PTSD) is a psychiatric chronic disease developing in individuals after the experience of an intense and life-threatening traumatic event. The post-traumatic symptomatology encompasses alterations in memory processes, mood, anxiety and arousal. There is now consensus in considering the disease as an aberrant adaptation to traumatic stress. Pharmacological research, aimed at the discovery of new potential effective treatments, has lately directed its attention towards the "so-called" cognitive enhancers. This class of substances, by modulating cognitive processes involved in the development and/or persistence of the post-traumatic symptomatology, could be of great help in improving the outcome of psychotherapies and patients' prognosis. In this perspective, drugs acting on the endocannabinoid system are receiving great attention due to their dual ability to modulate memory processes on one hand, and to reduce anxiety and depression on the other. The purpose of the present review is to offer a thorough overview of both animal and human studies investigating the effects of cannabinoids on memory processes. First, we will briefly describe the characteristics of the endocannabinoid system and the most commonly used animal models of learning and memory. Then, studies investigating cannabinoid modulatory influences on memory consolidation, retrieval and extinction will be separately presented, and the potential benefits associated with each approach will be discussed. In the final section, we will review literature data reporting beneficial effects of cannabinoid drugs in PTSD patients.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 059066087

Download citation: RISBibTeXText

PMID: 27456243

DOI: 10.1016/j.phrs.2016.07.024

Related references

The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD). Frontiers in Behavioral Neuroscience 7: 100, 2013

The risk for PTSD: new findings. New studies explore the high rate of post-traumatic stress disorder (PTSD) in women and an unexpected association between IQ and PTSD risk. Harvard Mental Health Letter 23(8): 1-5, 2007

Sympathetic system modulation to treat post-traumatic stress disorder (PTSD): a review of clinical evidence and neurobiology. Journal of Affective Disorders 142(1-3): 1-5, 2012

Post-traumatic Stress Disorder Post Partum: The Impact of Birth on the Prevalence of Post-traumatic Stress Disorder (PTSD) in Multiparous Women. Geburtshilfe und Frauenheilkunde 72(1): 56-63, 2012

The effect of the magical hour on post-traumatic stress disorder (PTSD) in traumatic childbirth: a clinical trial. Journal of Reproductive and Infant Psychology 34(4): 403-412, 2016

Novel therapeutic approach for the treatment of post-traumatic stress disorder (PTSD): facilitating fear extinction. Nihon Shinkei Seishin Yakurigaku Zasshi 32(4): 195-201, 2012

A novel therapeutic approach for the treatment of post-traumatic stress disorder (PTSD): enhancing the impaired extinction of fear memory. Nihon Shinkei Seishin Yakurigaku Zasshi 29(3): 135-139, 2009

Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson Trauma Scale, Clinical Global Impressions and the Clinician-Administered PTSD scale. International Clinical Psychopharmacology 19(2): 85-87, 2004

Post Traumatic Stress Disorder and Substance Use Disorder as Two Pathologies Affecting Memory Reactivation: Implications for New Therapeutic Approaches. Frontiers in Behavioral Neuroscience 13: 26, 2019

Validation of post-traumatic stress disorder (PTSD) and complex PTSD using the International Trauma Questionnaire. Acta Psychiatrica Scandinavica 136(3): 313-322, 2017

Co-morbidity: lessons learned about post-traumatic stress disorder (PTSD) from developing PTSD scales for the MMPI. Journal of Clinical Psychology 45(5): 709-717, 1989

Clinical evaluation of paroxetine in post-traumatic stress disorder (PTSD): 52-week, non-comparative open-label study for clinical use experience. Psychiatry and Clinical Neurosciences 62(6): 646-652, 2008

Neuropharmacology special issue on posttraumatic stress disorder (PTSD): current state of the art in clinical and preclinical PTSD research. Neuropharmacology 62(2): 539-541, 2012

Post-traumatic stress disorder (PTSD) among Filipino boys subjected to non-therapeutic ritual or medical surgical procedures: A retrospective cohort study. Annals of Medicine and Surgery 42: 19-22, 2019

The dissociative post-traumatic stress disorder (PTSD) subtype: A treatment outcome cohort study in veterans with PTSD. British Journal of Clinical Psychology 57(2): 203-222, 2018